You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
和鉑醫藥-B(02142.HK)公佈年度業績:全年收入大幅增長
格隆匯 03-29 18:11

格隆匯3月29日丨和鉑醫藥-B(02142.HK)發佈年度業績公吿,截至2020年12月31日止年度,集團錄得收入1410萬美元。集團的研發開支為5520萬美元,上年度則為4950萬美元。公司的總收入大幅增加至1410萬美元,主要由於公司的分子許可費中確認的收入增加。公司的分子許可費從上年度的270萬美元增加至該年度的1280萬美元,主要是由於公司與華蘭基因及艾伯維的授權合作協議。

商務拓展方面,報吿期內,公司繼續擴大與全球領先學術機構開展業務合作並精選專注於創新和效率的產業夥伴。公司相信,圍繞公司的專有技術和平台建立的靈活商業模式,能夠並將利用公司合作伙伴的互補優勢,使公司的平台價值最大化。

聯合合作伙伴就中和抗體HBM9022的共同開發與艾伯維(紐交所代碼:ABBV)於2020年6月達成戰略合作,該抗體可以有效阻斷SARS-CoV-2及SARS-CoV病毒感染。目前公司及其合作伙伴已於2020年12月授權艾伯維該產品的全球權益,且艾伯維已於2020年12月進入臨牀一期研究並完成首次給藥。

公司表示,自成立以來,公司致力於為全球患者研發創新療法,成為具有核心技術優勢和差異化產品管線的創新生物製藥公司。2021年,公司將進一步加速推進產品管線開發。公司將推進核心產品巴託利單抗和特那西普的多項臨牀試驗,併為未來的商業投放夯實基礎。相關準備工作已經開始啟動。

同時,公司另一項支柱資產HBM4003,亦是全球歷史上首個進入臨牀開發的全人源僅重鏈抗體,於報吿期內獲得中美多個單藥及聯合用藥的臨牀申請許可,預計將於2022年啟動全球範圍內的註冊性臨牀研究。

公司將繼續投資HBM4003,以及由公司發現引擎產生的其他新分子項目。未來,公司預計每年將有至少兩個新產品申報IND,通過HarbourMice®這一高效藥物發現引擎,公司將持續發現創新的優質候選分子。隨着臨牀前產品的成熟,公司計劃逐步建立內部生產能力和商業化能力,從中試規模到商業化生產。這是一個階段性的長期計劃,以滿足集團快速發展的需要。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account